Repertoire Immune Medicines

View the org chart displaying its 14 main executives

Most searched biographies at Repertoire Immune Medicines

• Torben Nissen, Chief Executive Officer
• Doug Cole, Director
• JC Gutierrez-Ramos, Director

Create your alert
to follow the executive moves at Repertoire Immune Medicines.

Repertoire Immune Medicines has 2,284 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Karius has just announced a $100 Million fundraising (posted on May 3 2024).
• Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
• WindRose Health Investors has announced the acquisition of SubjectWell  (posted on May 2 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Repertoire Immune Medicines

• Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases • Repertoire Immune Medicines
• Repertoire® Immune Medicines Presents New Data From Its DECODE™ Platform Identifying Highly Prevalent Immunotherapeutic Targets in HPV-Positive Cancers, Unlocking Pathways for Potential Therapeutics • Repertoire Immune Medicines
• Torben Straight Nissen Joins Repertoire® Immune Medicines as Chief Executive Officer • Repertoire Immune Medicines
• New Data From Repertoire® Immune Medicines Demonstrate Effectiveness of Its DECODE™ Platform to Characterize and Identify New Immunotherapeutic Targets in HPV Positive Cancer • Repertoire Immune Medicines
• Repertoire® Immune Medicines Enters New Research Collaboration to Discover The T Cell Response to Therapy in HPV-Associated Cancers • Repertoire Immune Medicines
• Repertoire® Immune Medicines Identifies Novel Immune Targets in Pathogenesis of Type 1 Diabetes • Repertoire Immune Medicines
• Preclinical Research Published in SCIENCE ADVANCES Demonstrates Repertoire Immune Medicines’ Cell-tethering Technology Delivers Potent Interleukin-12 Directly to Solid Tumors Potentially Improving Effectiveness of Cellular Immunotherapies • Repertoire Imm
• https://s3.us-east-1.amazonaws.com/repertoire-assets.investeddigital.com/downloads/Repertoire-SITC-PRESS-RELEASE_FINAL_6-Nov-2020.pdf
• https://assets.website-files.com/5ced5bd7efec584ab6889c10/5e8cdcf19cd40fc9a661a001_JDRF%20T1D%20Fund%20Repertoire%20Press%20Release_Final.pdf
• Press Releases
• View more press releases Close

Social media about Repertoire Immune Medicines

• Repertoire Immune Medicines on Wikipedia, Google News & Yahoo Finance
• Repertoire Immune Medicines on LinkedIn, Twitter & YouTube

Contact by email its executives including Susan Hockfield

Call Repertoire Immune Medicines at +1 61...

View the org chart

Register to receive your alert

Report an error